Opus Genetics advances five gene therapy programs with four clinical data readouts expected in 2027
Opus Genetics highlighted its expanding pipeline for inherited retinal diseases with three new programs entering clinical testing over the next 12-18 months and cash runway extending into 2029. The company's first-mover advantage across multiple rare disease indications and poten
View filing at SEC.gov →